PD-1 Antibody and JAK Inhibitor for New Hodgkin Lymphoma in Kids
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a combination of two drugs—a PD-1 antibody (which helps the immune system fight cancer) and a JAK inhibitor (which reduces inflammation)—in children ages 6–18 with newly diagnosed classic Hodgkin lymphoma who have never received cancer treatment before. The goal is to see if this combination works better than standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 6–18 years old
- Diagnosed with classic Hodgkin lymphoma (confirmed by biopsy), never treated before
- Has at least one measurable tumor visible on CT scan
- Blood counts and liver/kidney function meet minimum safe levels
- Able to swallow pills and absorb medicine normally
- No active autoimmune disease, hepatitis, HIV, or recent heart/stroke problems
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a PD-1 inhibitor (a type of immunotherapy) given after an autologous stem cell transplant can help prevent Hodgkin lymphoma from coming back in people at high risk of relapse.
This study tests a combination of a newer immunotherapy drug (nivolumab) with standard chemotherapy (AVD) in children, teens, and young adults with newly diagnosed, early-stage Hodgkin lymphoma—a blood cancer affecting lymph nodes. The goal is to see if adding immunotherapy improves outcomes while being tolerable for this age group.
This study tests a combination of the immunotherapy drug pembrolizumab with a chemotherapy regimen called GVD for patients whose Hodgkin's lymphoma has not responded or has returned after initial treatment. The goal is to see if this combination works better than standard approaches.
This trial tests a new treatment where your own immune cells are modified to better attack Hodgkin lymphoma cells. It is for people whose disease has not responded to other therapies.
This Phase 2 trial tests whether adding targeted immunotherapy to standard chemotherapy and radiation can improve outcomes in children with certain types of lymphoma. It may help the immune system work better against cancer.
This trial tests a combination of two medicines—azacitidine and a PD-1 inhibitor—for people with Hodgkin lymphoma that has returned or not responded to previous treatment. The aim is to see if this combination can help control the disease.
Hear when a new Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.